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Abstract
Haem oxygenase-1 (HO-1) up-regulation was suggested to reduce mucosal tissue damage in
inflammatory bowel disease (IBD) and an up-regulation of HO-1 expression in patients with Crohn's
disease (CD) and ulcerative colitis (UC) was demonstrated. A HO-1 gene promoter microsatellite
(GT)(n) dinucleotide repeat polymorphism was associated with regulation of HO-1 in response to
inflammatory stimuli. We therefore hypothesized that IBD patients might segregate into phenotypes
with high or low HO-1 inducibility. Ethylenediamine tetraacetic acid blood samples were obtained from
179 CD patients, 110 UC patients and 56 control patients without inflammation. Genomic DNA was
purified and the 5'-flanking region of the HO-1 gene containing the (GT)(n) dinucleotide repeat was
amplified. Polymerase chain reaction (PCR) products were purified and the length of the PCR fragments
was analysed. The number of (GT)(n) repeats in the population studied ranged from 13 to 42. The
distribution of the allele frequencies was comparable in patients and controls for both the short and the
long alleles. The frequencies of short-, middle- and long-sized alleles were not changed among the
groups studied. No correlation was found between IBD and microsatellite instability detected in five
individals. Our data indicate that (GT)(n) dinucleotide repeats of the HO-1 promotor region have no
significance for the pathophysiology and disease course of IBD.
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Heme oxygenase-1 (HO-1) up-regulation was suggested to reduce mucosal tissue 
damage in inflammatory bowel disease (IBD). An up-regulation of HO-1 expression in 
patients with Crohn´s disease (CD) and ulcerative colitis (UC) was demonstrated. A 
HO-1 gene promoter microsatellite (GT)n dinucleotide repeat polymorphism was 
associated with regulation of HO-1 in response to inflammatory stimuli. We therefore 
hypothesized that IBD patients might segregate into phenotypes with high or low HO-
1 inducibility.  
Methods:  
EDTA blood samples were obtained from 179 CD patients, 110 UC patients and 56 
control patients without inflammation. Genomic DNA was purified and the 5´-flanking 
region of the HO-1 gene containing the (GT)n dinucleotide repeat was amplified. PCR 
products were purified and length of the PCR fragments was analyzed.  
Results:  
The number of (GT)n repeats in the population studied ranged from 13 to 42. The 
distribution of the allele frequencies was comparable in patients and controls for both 
the short and the long allele. The frequencies of short-, middle- and long-sized alleles 
were not changed among studied groups. No correlation was found between IBD and 
microsatellite instability detected in 5 individals.  
Conclusion:  
Our data indicate that (GT)n dinucleotide repeats of the HO-1 promotor region have 
no significance for the pathophysiology and disease course of IBD. 




Heme oxygenase-1 (HO-1) has attracted attention because of its anti-inflammatory 
property. Regarding inflammatory bowel disease (IBD) HO-1 up-regulation was 
suggested to ameliorate recovery by reducing mucosal tissue damage caused by an 
enduring exposure to reactive oxygen metabolites provoking oxidative stress [1]. HO-
1 is the rate limiting enzyme in the conversion of heme into the potential antioxidants 
biliverdin/bilirubin, iron and carbon monoxide [2-4]. An up-regulation of HO-1 
expression in patients with Crohn´s disease (CD) and ulcerative colitis (UC) could be 
demonstrated [5]. However, differences in the expression pattern of HO-1 could only 
be detected in IBD patients with severely inflamed mucosa versus diverticulitis and 
intestinal ischaemia as non-specific inflammatory controls. HO-1 is one of the major 
acute phase proteins that is up-regulated by a whole variety of inducers such as 
endotoxin, hydrogen peroxide, prostaglandins and cytokines (interleukin-1, tumor 
necrosis factor) known to be detectable during IBD. 
Several in vivo models strongly support that HO-1 provides a potent cytoprotective 
effect. HO-1 knock out mice do not survive to term and mice that do survive to 
adulthood are abnormal and die within a year demonstrating signs of chronic 
inflammation in numerous organs [6;7]. A preventive HO-1 up-regulation in the 
established model of acute dextran sulphate sodium (DSS)-induced colitis caused an 
anti-inflammatory effect [5]. However, no protective effect could be detected in a 
therapeutic approach when HO-1 upregulation was induced after the onset of acute 
DSS-induced colitis or in chronic DSS-induced colitis. The protective role of HO-1 
has been demonstrated indirectly in the acute model of trinitrobenzene sulphonic 
acid (TNBS)-induced colitis in rats [8]. In these experiments inhibition of HO-1 prior to 
the induction of colitis by TNBS significantly increased the colonic inflammation. The 
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production of free radicals and the iNOS expression was significantly up-regulated, 
suggesting that HO-1 plays a role in attenuating experimental colitis. 
In vitro experiments support that HO-1 provides a mechanism in the protection of 
epithelial cells from apoptosis. Epithelial cell apoptosis has been demonstrated in 
DSS-induced colitis and is accompanied by a significant expression of the pro-
apoptotic molecules Fas, Bax and p53 [9]. Induced up-regulation of HO-1 in a colonic 
carcinoma epithelial cell line (HT-29) resulted in a down-regulation of Fas-mediated 
caspase-3 activation [5]. Similar results were obtained with freshly isolated murine 
islets cells and a pancreatic cell line [9;10]. 
Thus, presently available data suggest a protective effect of HO-1 induction and an 
up-regulation of HO-1 expression in patients with inflamed intestinal mucosa. 
Interestingly, a HO-1 gene promoter microsatellite polymorphism was suggested to 
be associated with restenosis after angioplasty [11] and was identified as vascular 
anti-inflammatory factor [12]. (GT)n dinucleotide repeat polymorphism of the HO-1 
promotor region that modulates the level of HO-1 inducibility was investigated. Short 
GT repeats (< 25) were associated with highly significant up-regulation of HO-1 in 
response to inflammatory stimuli [11;12].  
We hypothesized that patients may segregate into phenotypes with high and low HO-
1 inducibility providing more or less antioxidants respectively. As HO-1 may present 
an anti-inflammatory factor regulating colonic inflammation, we investigated variants 
of the HO-1 promotor region in 179 CD patients, 110 UC patients and 56 control 
patients without inflammation.  
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Materials and Methods 
 
Patients 
Blood samples from age – matched individuals were obtained from 179 CD patients, 
110 UC patients and 56 control patients without inflammation from the German IBD 
competence network serum bank (Core facility Regensburg). The study was 
approved by the University of Regensburg Ethics Committee.  
 
DNA-isolation  
Genomic DNA was purified from human whole blood samples with the QIAamp DNA 
Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer´s protocol. 
Briefly, DNA was isolated following cell lysis and proteinase K digestion (56°C, 10 
min). DNA was loaded on a QIAamp spin column, washed twice and eluted in 200 μl 
distilled water. 
 
HO-1 genotype assessment 
The 5´-flanking region of the HO-1 gene containing the (GT)n dinucleotide repeat was 
amplified as previously described [13]. Briefly, a PCR was performed using as 
forward primer 1 μl 5´-CAG CTT TCT GGA ACC TTC TGG-3´ (5 μM), carrying a 6-
FAM fluorescent label (MWG biotech, Ebersberg, Germany), and as downstream 
primer 1 μl 5´-GAA ACA AAG TCT GGC CAT AGG AC-3´ (5 μM). Genomic DNA and 
primers were mixed in a 50 μl reaction including 1 μl dNTP (10 μM each, BD 
Biosciences Clontech, Heidelberg, Germany) and 1 μl Advantage™-HF2 Polymerase 
Mix (BD Biosciences Clontech, Heidelberg, Germany) in the recommended buffer. 
After pretreatment at 94°C for 10 min the PCR comprised 30 cycles with denaturing 
at 94°C for 30 seconds, annealing at 60°C for 30 seconds, extension at 68°C for 30 
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seconds and concluded with a extension step at 68°C for 30 min. The reactions were 
performed in a TRIO-Thermoblock (Biometra, Goettingen, Germany). PCR products 
were purified with the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany). 
Sequence analysis of the amplification product of an individual homozygous for the 
211 base pair alleles showed correspondence with 23 (GT)n dinucleotide repeats 
(results not shown). Dinucleotide repeats were calculated as (PCR fragment length in 
bp – 165) / 2 = numbers of (GT)n. Length of the PCR fragments was analyzed by the 
Medigenomix corporation (Planegg, Germany, figure 1). The number of GT repeats 
was identified by sizing of PCR products with the ABI 310 sequencer and the 
Genescan Analysis 2.1 software (Applied Biosystems, Foster City, CA). 
 
Statistical analysis 
For statistical analyses the SigmaPlot 2002 software package (version 8.02, Systat 
Software Inc. (SSI), San Jose, California, USA) was used. Percentages of allele 
frequencies are presented as box plots graph data with the median, the 25th and 75th 
percentile. Whiskers above and below the box indicate the 90th and 10th percentiles. 
Significances were calculated with Student`s unpaired t – test considered successful 
for p < 0.05. 
 




Allele frequencies of the HO-1 (GT)n dinucleotide repeat polymorphism 
The numbers of (GT)n dinucleotide repeats in the human HO-1 promotor was 
analyzed via length determination of an according PCR fragment (figure 1). The 
number of repeats in the population studied ranged from 13 to 42 (figure 2). The 
distribution of the allele frequencies was comparable in patients and controls for both 
the short and the long allele.  
 
Allele frequency distribution 
The distribution of GT repeats in the HO-1 promotor region among the studied 
individuals is shown in figure 3A. In the three groups, the 23 and 30 GT repeats were 
the most common alleles. Three allele subclasses according to the number of GT 
repeats were set: short-sized alleles (S) with less than 23 repeats, middle-sized 
alleles (M) with 23 - 32 GT repeats and long-sized alleles (L) with 33 – 42 repeats. 
The frequencies of different-sized alleles were compared between studied groups 
(figure 3B). The middle-sized alleles are shown to appear more often but were not 
varying among studied groups. 
 
Microsatellite instability  
Comparison of amplified DNA from blood samples of CD-, UC- and control patients 
allowed identification of microsatellite instability due to multiple PCR fragment 
lengths. Among the 179 CD patients analysed, 4 (2%) exhibited a microsatellite 
instability phenotype. The remaining 172 (98%) were classified as exhibiting a 
microsatellite stable phenotype. The number of GT repeats in the HO-1 promotor 
region showed a distribution range from 15 to 31 (median 26.5 ± 3.9). This was not 
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significantly different compared to stable phenotypes (median 28.5 ± 3.7). None of 
the 110 UC patients showed microsatellite instability. One control patient among the 
56 tested (2%) displayed microsatellite instability (range 23 to 31, median 27 ± 2.7 
compared to stable phenotypes 28 ± 3.9).  
The frequencies of microsatellite instability was comparable in CD patients and 
controls. Individuals with microsatellite instability were excluded from allele frequency 
distribution analysis. 
 




In the present study we investigated (GT)n dinucleotide repeats of the HO-1 promotor 
region in IBD patients to prove wether individuals segregate into phenotypes with 
high and low HO-1 inducibility. We found no relationship between the frequency 
distribution and IBD and a lack of influence on disease course. The distribution of the 
(GT)n dinucleotide repeats among studied groups is stunningly similar to previous 
findings [14] demonstrating the 23 and 30 GT repeats as the most common alleles. 
Also the range of GT repeats found showed the expected allocation. Microsatellite 
instability was found but had no significance concerning IBD.  
Lavrovsky et. al. identified nuclear factor-kappa B (NF-κB) and AP-2-like binding sites 
in the 5' untranslated region of the human HO-1 gene and confirmed binding of 
transcription factors by DNase I footprint analysis [15]. NF-κB is the main target of 
anti-inflammatory therapies in IBD and we could show the activation of this 
transcription factor during human mucosal inflammation in situ [16]. Accordingly Paul 
et. al. [5] could demonstrate an up-regulation of HO-1 expression in patients with CD 
and UC. Our data indicate that the different alleles of (GT)n repeats in the HO-1 
promotor region have no significance at least with regard to IBD. 
HO-1 is widely expressed in organs and tissues. It seems to be a novel protective 
factor with an indisputable potent anti-inflammatory and anti-oxidant effect. There has 
been increasing recognition of HO-1 promoter polymorphisms leading to reduced HO-
1 expression may be associated with an increased risk of a variety of diseases. 
Longer (GT)n repeats were reported to be associated with higher susceptibility to the 
development of malignant tumors [17;18] or coronary artery atherosclerosis [19]. 
Contrary to the results for IBD presented in this work certain other inflammatory  
diseases may be associated with the size of (GT)n repeats. Yasuda et al [20] found 
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an association of long-sized alleles with susceptibility to pneumonia in the older 
Japanese population. Yamada et al [21] investigated the correlation between the 
length of the (GT)n repeats and susceptibility to the development of chronic 
pulmonary emphysema. He described that long-sized alleles may reduce HO-1 
inducibility by reactive oxygen species in cigarette smoke, thereby resulting in the 
development of chronic pulmonary emphysema. 




Figure 1: Amplified region of the HO-1 promotor containing the (GT)n dinucleotide 
repeat. Alleles from a patient with 207 and 213 base pairs according to 21 and 24 
(GT)n dinucleotide repeats respectively (upper plot). DNA standard (lower plot). 
 
Figure 2: Allele frequencies of the HO-1 promotor (GT)n dinucleotide repeats. 
 
Figure 3: Frequency distribution of HO-1 promotor (GT)n dinucleotide repeats. (A) 
Individual allele pattern. (B) Distribution of short- (S), middle- (M) and long-sized (L) 
GT repeats. Control patients (white columns), UC patients (grey columns) and CD 
patients (black columns). 
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